Novel use as a pharmaceutical composition for preventing and treating fibrosis using the epithelial-mesenchymal transition inhibitory activity of chromone derivatives

摘要

The present invention relates to a novel use as a pharmaceutical composition for the prevention and treatment of fibrosis utilizing the epithelial mesenchymal transition (EMT) inhibitory activity of a chromone derivative, and more specifically, the chromone derivative is an epithelial mesenchymal The novel discovery of the ability to inhibit migration relates to the novel use of such activity as a preventive and therapeutic agent for fibrosis. The pharmaceutical composition of the present invention can effectively suppress the activation of the epithelial-mesenchymal transition by containing the chromone derivative of the chemical formula 1 as an active ingredient, whereby the activation of the epithelial-mesenchymal transition can be achieved. The induced fibrosis of organs or tissues can be effectively suppressed. In particular, since cells that have already become fibrosed can be returned to their original normal form, it is not only to prevent or deal with fibrosis initially, but also to treat middle- or late-stage symptoms in which fibrosis progresses. Can. [Selected figure] Figure 11